Small molecule activation of m6A mRNA methylation as a novel approach for neuroprotection
Li-Ying YuiD, Simona SelbergiD, Indrek TeinoiD, Jin Han NamiD, Larisa B. IvanovaiD, Brunaldo RenziiD, Neinar Seli, Esko M KankuriiD, Merja H. VoutilaineniD, Mati M. KarelsoniD, Märt SaarmaiD
Abstract
N6-Methyladenosine (m6A) is the most common mRNA base modification in eukaryotes. Methylation of adenosine residues to m6A contributes to the regulation of splicing, transport, stability, and translation of mRNA and two main classes of enzymes regulate it. The formation of m6A is catalysed by a methyltransferase complex containing methyltransferase-like 3 (METTL3), METTL14, and Wilms tumour 1-associated protein (WTAP) as well as monomeric METTL16. Demethylation of m6A is catalysed by the fat mass and obesity-associated protein FTO and the RNA demethylase AlkB homolog 5 (ALKBH5). The m6A mRNA methylation dysregulation occurs in the nervous system and in Parkinsons disease (PD), but it remains poorly studied. Moreover, the role of m6A mRNA methylation in neuronal survival, neuroprotection, and neuroregeneration is unclear. We have earlier used high-throughput virtual screening of large compound libraries and identified four unique small-molecule ligands that activate m6A mRNA methylation by binding to the METTL3/14/WTAP complex and enhancing the binding of the methylation substrate SAM to nanomolar concentrations. Following this, we now discovered that two methyltransferase activators at 10 nM concentrations supported the survival and protected dopamine (DA) neurons in culture in growth factor deprivation and 6-hydroxydopamine (6-OHDA) neurotoxin models. In contrast, METTL3/14 inhibitor STM2457 triggered death of DA neurons. For clinical translation we also tested the most efficient compound C4 on induced pluripotent stem cell-derived human DA neurons and in animal model of Parkinsons disease (PD). C4 compound protected human DA neurons from 6-OHDA-induced cell death and increased neurite outgrowth and the number of processes demonstrating that it has both neuroprotective and neurorestorative properties. METTL3/14 activator C4 improved motor behaviour and protected DA neurons and their fibres faster and much more efficiently than GDNF in the rat 6-OHDA model of PD. These are the first specific activators of METTL3/14/WTAP and first demonstration that m6A regulators can protect and regenerate neurons. These data demonstrate that m6A mRNA methylation is a novel pathway regulating neuronal survival and regeneration.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 6
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Effect of RNA m6A methyltransferase activation by a low molecular weight compound on anxiety- and depression-related behaviours, monoamine neurochemistry and striatal gene expression in the rat
M. Kanarik, K. Liiver, … J. Harro·bioRxiv·Jan 8, 2024
- Rewired m6A methylation of promoter antisense RNAs in Alzheimer disease regulates global gene transcription in the 3D nucleome
Benxia Hu, Yuqiang Shi, … Wenbo Li·bioRxiv·Mar 22, 2025
- YTHDF1 mediates translational control by m6A mRNA methylation in adaptation to environmental challenges
Zhuoyue Shi, Kailong Wen, … Xiaoxi Zhuang·Proceedings of the National Academy of SciencesPeer-reviewed·Apr 13, 2026
- Small-molecule inhibitors of the RNA m6A demethylase FTO potently support the survival of dopamine neurons
Simona Selberg, Li-Ying Yu, … Mati M. Karelson·International Journal of Molecular SciencesPeer-reviewed·Apr 26, 2021
- Synaptic control of DNA-methylation involves activity-dependent degradation of DNMT3a1 in the nucleus
Gonca Bayraktar, PingAn Yuanxiang, … Michael R. Kreutz·NeuropsychopharmacologyPeer-reviewed·Jul 29, 2020
- NMDAR mediated dynamic changes in m6A inversely correlates with neuronal translation
Naveen Kumar Chandappa Gowda, Bharti Nawalpuri, … Ravi Sondekoppa Muddashetty·Scientific ReportsPeer-reviewed·Jul 5, 2022